Energy balance at the organism and cellular level: effects of biguanides by Michael Pollak
ORAL PRESENTATION Open Access
Energy balance at the organism and cellular level:
effects of biguanides
Michael Pollak
From Metabolism, Diet and Disease 2014: Cancer and metabolism
Washington DC, USA. 28-30 May 2014
Metformin, an inhibitor of OXPHOS, is widely used for
treatment of type II diabetes (T2D). A key site of action
in diabetes treatment is liver, where the drug achieves a
relatively high concentration following oral administra-
tion, leading to inhibition of gluconeogenesis and reduc-
tion of the hyperglycemia and hyperinsulinemia of T2D.
As high levels of insulin have been associated with poor
prognosis of prostate, breast, and colon cancer and as
early retrospective pharmaco-epidemiologic studies sug-
gested reduced cancer burden among diabetics treated
with metformin relative to other diabetes treatments,
the hypothesis that metformin or other biguanides could
be useful in cancer prevention or treatment has received
considerable attention. However, it is not clear if met-
formin at conventional anti-diabetic doses administered
to non-diabetic subjects has effects of sufficient magni-
tude on levels of insulin or other candidate mediators to
influence cancer biology. Drugs used for androgen
deprivation in prostate cancer treatment and most PI3K
inhibitors provide examples of therapies that induce
hyperinsulinemia which may attenuate therapeutic bene-
fit, justifying study of combinations of each of these
with biguanides. The separate hypothesis that biguanides
can directly influence cancer cell metabolism is attractive,
as this mechanism has been shown to operate in many
laboratory models - yet there is uncertainty if metformin
administered at conventional anti diabetic doses achieves
sufficient concentrations in extra-hepatic tissues or can-
cers to perturb their cellular energy metabolism. There-
fore, studies of maximally tolerated doses of biguanides
with more favourable pharmacokinetic properties than
metformin may be necessary if the “direct action”
hypothesis is to be clinically tested. Recent work is identi-
fying contexts where ‘direct’ actions of biguanides as
inhibitors of OXPHOS may be of particular therapeutic
benefit. For example, there is evidence that tumours
using glutamine as a carbon source are relatively sensitive
to biguanides, that high ambient glucose levels are asso-
ciated with reduced sensitivity, and that serine deficiency
enhances the anti-proliferative actions of biguanides.
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